Development and implementation of a cell-based assay to discover agonists of the nuclear receptor REV-ERBα
Main Article Content
Keywords
nuclear receptor, REV-ERBα, luciferase reporter, assay development, drug discovery, high throughput screening
Abstract
The nuclear receptors are transcription factors involved in the regulation of a variety of physiological processes whose activity can be modulated by binding to relevant small molecule ligands. Their dysfunction has been shown to play a role in disease states such as diabetes, cancer, inflammatory diseases, and hormonal resistance ailments, which makes them interesting targets for drug discovery. The nuclear receptor REV-ERBα is involved in regulating the circadian rhythm and metabolism. Its natural ligand is heme and there is significant interest in identifying novel synthetic modulators to serve as tools to characterize its function and to serve as drugs in treating metabolic disorders. To do so, we established a mammalian cell-based two-hybrid assay system capable of measuring the interaction between REV-ERBα and its co-repressor, nuclear co-repressor 1. This assay was validated to industry standard criteria and was used to screen a subset of the LOPAC®1280 library and 29568 compounds from a diverse compound library. Profiling of the primary hits in a panel of counter and selectivity assays confirmed that REV-ERBα activity can be modulated pharmacologically and chemical scaffolds have been identified for optimization.
Downloads
Metrics
References
2. Burris TP, McCabe ERB (2001) Nuclear Receptors and Genetic Disease. Academic Press, San Diego, pp. 1-274.
3. Burris TP (2008) Nuclear hormone receptors for heme: REV-ERBalpha and REV-ERBbeta are ligand-regulated components of the mammalian clock. Molecular Endocri 22: 1509-1520.
4. Yang X, Lamia KA, Evans RM (2007) Nuclear Receptors, Metabolism, and the Circadian Clock. Cold Spring Harbor Symposia Quant Biol 72: 387-394.
5. Kliwer SA, Lehmann JM, Willson TM (1999) Orphan nuclear receptors: shifting endocrinology into reverse. Science 284: 757-760.
6. Burris TP, Busby SA, Griffin PR (2012) Targeting orphan nuclear receptors for treatment of metabolic diseases and autoimmunity. Chem Biol 19: 51-59.
7. Karlsson B, Knutsson A, Lindahl B (2001) Is there an association between shift work and having a metabolic syndrome? Results from a population based study of 27 485 people. Occup Environ Med 58: 747-752.
8. De Bacquer D, Van Risseghem M, Clays E, Kittel F, De Backer G, Braeckman L (2009) Rotating shift work and the metabolic syndrome: a prospective study. Int J Epidemiol 38: 848-854.
9. Brum MC, Filho FF, Schnorr CC, Bottega GB, Rodrigues TC (2015) Shift work and its association with metabolic disorders. Diabetol Metab Syndr 7:45.
10. Cho H, Zhao X, Hatori M, Yu RT, Barish GD, et al. (2012) Regulation of circadian behaviour and metabolism by REV-ERB-α and REV-ERB-β. Nature 485: 123-127.
11. Duez H, Staels B (2009) Rev-erb-α: an integrator of circadian rhythmus and metabolism. J. Appl Physiol 107: 1972-1980.
12. Duez H, Staels B (2010) Nuclear Receptors Linking Circadian Rhythmus and Cardiometabolic Control. Arterioscler Thromb Vasc Biol 30: 1529-1534.
13. Kojetin DJ, Burris TP (2014) REV-ERB and ROR nuclear receptors as drug targets. Nature Reviews Drug Discovery 13: 197-216.
14. Meng QJ, McMaster A, Beesley S, Lu WQ, Gibbs J, et al. (2008) Ligand modulation of REV-ERBαfunction resets the peripheral circadian clock in a phasic manner. J Cell Sci 121: 3629-3635.
15. Kumar N, Solt LA, Wang Y, Rogers PM, Bhattcharyya G, et al. (2010) Regulation of Adipogenesis by Natural and Synthetic REV-ERB Ligands. Endocrinology 151: 3015-3025.
16. Grant D, Yin L, Collins JL, Parks DJ, Orband-Miller LA, , et al. (2010) GSK4112, a small molecule chemical probe for the cell biology of the nuclear heme receptor Rev-erbα. ACV Chem Biol 5: 925-932.
17. Noel R, Song X, Shi Y, Banerjee S, Kojetin D, et al. (2012) Synthesis and SAR of tetrahydroisoquinolines as Rev-erbα agonists. Bioorg Med Chem Lett 22: 3739-3742.
18. Shin Y, Noel R, Banerjee S, Kojetin D, Song X, et al. (2012) Small molecule tertiary amines as agonists of the nuclear hormone receptor Rev-erbα. Bioorg Med Chem Lett 22: 4413-4417.
19. Solt LA, Wang Y, Banerjee A, Hughes T, Kojetin DJ, et al. (2012) Regulation of circadian behavior and metabolism by synthetic REV-ERB agonists. Nature 485: 62-68.
20. Yoo SH, Yamazaki S, Lowrey PL, Shimomura K, Ko CH, et al. (2004) PERIOD2::LUCIFERASE real time reporting of circadian dynamics reveals persistent circadian oscillations in mouse peripheral tissues. Proc Natl Acad Sci USA 101: 5339-5346.
21. Lien F, Berthier A, Bouchaert E, Gheeraert C, Alexandre J, et al. (2014) Metformin interferes with bile acid homeostasis through AMPK-FXR crosstalk. J Clin Invest 124: 1037-1051.
22. Berthier A, Oger F, Gheeraert C, Boulahtouf A, Le Guével R, et al. (2012) The novel antibacterial compound walrycin A induces human PXR transcriptional activity. Toxicol Sci 127:225-235.
23. Sulli G, Rommel A, Wang X, Kolar MJ, Puca F, et a. (2018) Pharmacological activation of REV-ERBs is lethal in cancer and oncogene-induced senescence. Nature 553:351-355.
24. Zhang JH, Chung TD, Oldenburg KR (1999). A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 4: 67-73.
25. Bellet MM, Sassone-Corsi P (2010) Mammalian circadian clock and metabolism – the epigenetic link. J. Cell Science 123:3837-3848.
26. Duez H, Staels B (2008) Rev-erbα gives a time cue to metabolism. FEBS Letters 582: 19-25.
27. Feng D, Lazar MA (2012) Clocks, Metabolism, and the Epigenome. Molecular Cell 47: 158-167.
28. Farrow SN, Solari R, Willson TM (2012) The importance of chronobiology to drug discovery. Expert Opin Drug Discov 7: 535-541.
29. Sittampalam GS, Coussens NP (Ed). Assay Guidance Manual, Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004-.
30. Maddox CB, Rasmussen L, White EL (2008) Adapting Cell-Based Assays to the High Throughput Screening Platform: Problems Encountered and Lessons Learned. JALA Charlottesv Va 13:168-173.
31. De Mei C, Ercolani L, Parodi C, Veronesi M, Lo Vecchio C, et al. (2015) Dual inhibition of REV-ERBβ and autophagy as a novel pharmacological approach to induce cytotoxicity in cancer cells. Oncogene 34: 2597-2608.
Article Sidebar
Article Details
Authors who publish with JBM agree to the following terms:
- Authors retain copyright and grant JBM right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
Yuliya Hering, Fraunhofer Institute for Molecular Biology and Applied Ecology, ScreeningPort (Fraunhofer-IME SP), Schnackenburgallee 114, D-22525 Hamburg, Germany.
Dr. Sheraz Gul is Head of Drug Discovery, Assay Development & Screening at the Fraunhofer Institute for Molecular Biology and Applied Ecology. He is responsible for the global management of drug discovery activities and has 23 years
